CRISPR Therapeutics AG (CRSP) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CRSP Revenue Growth
Revenue Breakdown (FY 2025)
CRSP's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CRSP Revenue Analysis (2014–2025)
As of May 7, 2026, CRISPR Therapeutics AG (CRSP) generated trailing twelve-month (TTM) revenue of $4.1 million, reflecting explosive growth of +68.6% year-over-year. The most recent quarter (Q1 2026) recorded $1.5 million in revenue, up 68.8% sequentially.
Looking at the longer-term picture, CRSP's 5-year compound annual growth rate (CAGR) stands at +37.3%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $913.1 million in 2021.
Revenue diversification analysis shows CRSP's business is primarily driven by Grant (100%). With over half of revenue concentrated in Grant, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including BEAM (+120.0% YoY), SGMO (-37.1% YoY), and PRME (+55.3% YoY), CRSP has underperformed the peer group in terms of revenue growth. Compare CRSP vs BEAM →
CRSP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CRSPCurrent | $4M | +68.6% | +37.3% | -16191.4% | |
 BEAM | $140M | +120.0% | +466.3% | -274.6% | |
 SGMO | $58M | -37.1% | -10.8% | -179.9% | |
 PRME | $5M | +55.3% | -2.3% | -4498.1% |
CRSP Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $3.5M | -90.0% | $-229,449,000 | -6537.0% | $-568,318,000 | -16191.4% |
| 2024 | $35.0M | -90.5% | $-75,250,000 | -215.0% | $-466,566,000 | -1333.0% |
| 2023 | $370.0M | +84762.4% | $239.8M | 64.8% | $-222,538,000 | -60.1% |
| 2022 | $436K | -100.0% | $-109,814,000 | -25186.7% | $-673,161,000 | -154394.7% |
| 2021 | $913.1M | +126893.2% | $811.9M | 88.9% | $373.5M | 40.9% |
| 2020 | $719K | -99.8% | $-268,688,000 | -37369.7% | $-354,435,000 | -49295.5% |
| 2019 | $289.6M | +9169.8% | $110.2M | 38.1% | $46.7M | 16.1% |
| 2018 | $3.1M | -92.4% | $-110,649,000 | -3541.9% | $-158,943,000 | -5087.8% |
| 2017 | $41.0M | +693.9% | $-28,803,000 | -70.3% | $-64,648,000 | -157.7% |
| 2016 | $5.2M | +1990.7% | $-37,074,000 | -717.9% | $-68,130,000 | -1319.3% |
See CRSP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRSP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRSP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRSP — Frequently Asked Questions
Quick answers to the most common questions about buying CRSP stock.
Is CRSP's revenue growth accelerating or slowing?
CRSP revenue is accelerating at +68.6% year-over-year, exceeding the 5-year CAGR of +37.3%. TTM revenue reached $4M. Growth momentum has increased versus prior periods.
What is CRSP's long-term revenue growth rate?
CRISPR Therapeutics AG's 5-year revenue CAGR of +37.3% reflects the sustained expansion pattern. Current YoY growth of +68.6% is above this long-term average.
How is CRSP's revenue distributed by segment?
CRSP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.